The Ali Massumi Cardiac Arrhythmia Symposium
There have been recent changes to the way we manage patients with atrial fibrillation (AF) and atrial flutter (AFL). Guidelines for the use of anticoagulants have been updated and expanded. There are non-pharmacologic therapies now available to prevent embolic strokes in patients who are at increased risk of bleeding. Catheter ablation for AF and AFL have become mainstream options with low risk. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, diagnosed in approximately 1% of the general population. AF is projected to affect over 7.5 million people in the United States (U.S.) by 2050 and poses a significant burden. Atrial fibrillation (AF) is a common cause of devastating but potentially preventable stroke. Among patients with AF without prophylaxis, the risk of stroke is 5 times higher than in persons free of the disease. Thromboprophylaxis with oral anticoagulants involving warfarin or other agents is the mainstay for stroke prevention, reducing the annual incidence of stroke in AF patients by more than 60%. However, thromboprophylaxis is generally under-utilized among AF patients. The goal of this symposium is to inform physicians about the recent updates to the guidelines for management of AF and AFL, including the various treatment to reduce the risk of stroke in patients with non-valvular atrial fibrillation and possible role of left appendage closure in decreasing burden of AF. It is important to highlight the different new strategies to manage AF and protect AF patients from stroke; improving the knowledge of adult cardiologist about Congenital Heart Disease; review the management of ventricular tachycardia, with the goal of improving diagnosis and management of this condition; also by reviewing the Subcutaneous ICD: Indications, implantation and complications, with the goal of providing a safe alternative option for patients needing an ICD to prevent lethal arrhythmias.
The Houstonian Hotel
111 North Post Oak Lane, Houston, TX